SCHEMBL6093084

SCHEMBL6093084

CCOC(=O)c1[nH]c(=O)n(C)c(=O)c1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
NPC1 O15118 2/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 4/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
TSHR P16473 1/20 0.48
MAPT P10636 2/20 0.44
STAT1 P42224 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756756 0.83 RAB9A (0.48) RAB9ANPC1KMT2AALDH1A1HSD17B10
SCHEMBL2354376 0.77 TUBB4A (0.59) RAB9ANPC1KMT2AALDH1A1HSD17B10
SCHEMBL3416727 0.76 KMT2A (0.46) KMT2AALDH1A1KDM4EHPGDGABRA1
SCHEMBL6093940 0.74 KDM4E (0.45) RAB9ANPC1KMT2AALDH1A1HSD17B10
SCHEMBL17848969 0.73 KDM4E (0.47) KMT2AALDH1A1TSHRMAPTKDM4E
SCHEMBL2512337 0.73 HPGD (0.47) KMT2AMAPTPOLBKDM4ESMN1; SMN2
SCHEMBL6093491 0.73 KDM4E (0.44) RAB9AKMT2AALDH1A1TSHRMAPT
SCHEMBL6093718 0.73 KDM4E (0.42) NPC1KMT2AALDH1A1HSD17B10MAPT
SCHEMBL18803837 0.72 GABRA1 (0.53) RAB9ANPC1KMT2AALDH1A1HSD17B10
SCHEMBL7453470 0.71 KMT2A (0.53) RAB9ANPC1KMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
WO-2004062613-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 RAB9A 1727/4885NPC1 866/4885KMT2A 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.